Improved 5-Fluorouracil Chemotherapy in Breast Cancer Patients by Monitoring Dihydropyrimidine Dehydrogenase Activity
Abstract
Dihydropyrimidine Dehydrogenase (DPD) is the initial, rate-limiting enzyme in catabolism of 5- fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The purpose of this project is to improve 5-FU-based chemotherapy by monitoring DPD.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1997
- Accession Number
- ADA335055
Entities
People
- Zhihong Lu
Organizations
- University of Alabama